Stock Monitor: Keryx Biopharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / February 08, 2018 / Active-Investors.com has just released a free earnings report on Illumina, Inc. (NASDAQ: ILMN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ILMN. Illumina reported its fourth quarter and fiscal 2017 operating and financial results on January 30, 2018. The genetic testing tools Company outperformed top- and bottom-line expectations and provided guidance for FY18. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), which also belongs to the Healthcare sector as the Company Illumina. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Illumina most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Earnings Highlights and Summary
For the fourth quarter fiscal 2017, Illumina's revenue surged 26% to $778 million compared to $619 million in Q4 2016. The Company's reported numbers exceeded analysts' estimates of $753.3 million.
For full year (FY) 2017, Illumina's revenue totaled $2.75 billion, reflecting a 15% increase compared to revenue of $2.40 billion in FY16.
Illumina's gross margin in Q4 2017 was 69.7% compared to 67.7% in Q4 2016. Excluding amortization of acquired intangible assets, the Company's non-GAAP gross margin was 70.9% for the reported quarter versus 69.5% in the prior year's comparable period.
During Q4 2017, Illumina's Research and development (R&D) expenses were $137 million compared to $130 million in Q4 2016. Excluding restructuring charges, the Company's non-GAAP R&D expenses as a percentage of revenue were 17.4% compared to 21.0% in the prior year's same period.
For Q4 2017, Illumina's selling, general, and administrative (SG&A) expenses came in at $175 million versus $146 million in Q4 2016. On an adjusted basis, the Company's SG&A expenses as a percentage of revenue were 22.1% in the reported quarter compared to 23.4% in the year earlier corresponding quarter.
During Q4 2017, GAAP net income attributable to Illumina's stockholders was $68 million, or $0.46 per diluted share, compared to $124 million, or $0.84 per diluted share, for Q4 2016. The Company's reported quarter results included provisional estimate of the one-time transition tax as a result of US tax reform. Non-GAAP net income attributable to Illumina's stockholders for the reported quarter was $212 million, or $1.44 per diluted share, compared to $126 million, or $0.85 per diluted share, for the year earlier same quarter. The Company's earnings surpassed Wall Street's estimates of $1.22 per share.
For FY17, GAAP net income attributable to Illumina's stockholders totaled $726 million, or $4.92 per diluted share, compared to $463 million, or $3.07 per diluted share, for FY16. The Company's non-GAAP net income attributable to stockholders was $591 million, or $4.00 per diluted share, compared to $503 million, or $3.33 per diluted share, in FY16.
During Q4 2017, Illumina's cash flow from operations totaled $294 million compared to $262 million in Q4 2016. The Company's free cash flow (cash flow from operations less capital expenditures) for the reported quarter came in at $218 million versus $180 million in the year earlier comparable quarter. In Q4 2017, Illumina repurchased $75 million of common stock under its share repurchase program.
Illumina's depreciation and amortization (D&A) expenses were $40 million and capital expenditures for free cash flow purposes were $76 million during Q4 2017. At the close of the quarter on December 31, 2017, the Company held $2.1 billion in cash, cash equivalents, and short-term investments compared to $1.6 billion as of January 01, 2017.
For fiscal 2018, Illumina is projecting revenue growth in the range of 13% to 14%. The Company is estimating GAAP earnings per diluted share attributable to Illumina's stockholders of $4.14 to $4.24 and non-GAAP earnings per diluted share attributable to Illumina's stockholders of $4.50 to $4.60.
Stock Performance Snapshot
February 07, 2018 - At Wednesday's closing bell, Illumina's stock slightly climbed 0.18%, ending the trading session at $221.20.
Volume traded for the day: 1.10 million shares, which was above the 3-month average volume of 869.36 thousand shares.
Stock performance in the last three-month – up 5.74%; previous six-month period – up 11.94%; past twelve-month period – up 35.83%; and year-to-date – up 1.24%
After yesterday's close, Illumina's market cap was at $33.78 billion.
Price to Earnings (P/E) ratio was at 44.89.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.